Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies

Advanced Drug Delivery Reviews

Volumn 103, Issue , 2016, Pages 5-19

  Sued, Omar ^a   Figueroa, María Inés ^a   Cahn, Pedro ^a  

^a FUNDACIÓN HUÉSPED   (Argentina)

Author keywords

HIV cure; HIV nanoformulations; Microbicides; Nanotechnology; Pre exposure prophylaxis; Treatment as prevention

Indexed keywords

CURING; CUTTING TOOLS; NANOTECHNOLOGY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIRETROVIRAL TREATMENT; CURRENT ESTIMATES; HIV NANOFORMULATIONS; MICROBICIDES; PATIENT MANAGEMENT; PRE-EXPOSURE; TREATMENT AS PREVENTION;

DISEASES;

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT; DARUNAVIR; DOLUTEGRAVIR; DORAVIRINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSTEMSAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IBALIZUMAB; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ATHEROSCLEROSIS; BONE DISEASE; CIRCUMCISION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; EPIDEMIC; FANCONI ANEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INJECTION SITE REACTION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER DISEASE; LIVER TOXICITY; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; VIRUS TRANSMISSION; VOMITING; DISEASE MANAGEMENT; MALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DISEASE MANAGEMENT; HIV INFECTIONS; HUMANS; MALE;

EID: 84965157556     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.016     Document Type: Review

References (223)

1. [1] UNAIDS, How AIDS Changed Everything. 2015.
2. [2] UNAIDS, AIDS by the Numbers 2015. 2015.
3. [3] UNAIDS, Terminology Guidelines. 2011, 1–31.
4. [4] Tanser, F., de Oliveira, T., Maheu-Giroux, M., Bärnighausen, T., Concentrated HIV subepidemics in generalized epidemic settings. Curr. Opin. HIV AIDS 9 (2014), 115–125, 10.1097/COH.0000000000000034.
5. [5] Leach-Kemon, K., Shepard, D., O'Rourke, K., VanderZanden, A., HIV Worldwide 1990-2013. J. Am. Med. Assoc., 314, 2015, 1552, 10.1001/jama.2015.12936.
6. [6] UNICEF, PAHO, WHO, Elimination of Mother-to-Child Transmission of HIV and syphilis in the Americas. 2015.
7. [7] Kazatchkine, M., Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia. J. Int. AIDS Soc., 17, 2014, 19501 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4224809&tool=pmcentrez&rendertype=abstract, accessed March 6, 2016).
8. [8] Cooper, A., García, M., Petrovas, C., Yamamoto, T., Koup, R.A., Nabel, G.J., HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 498 (2013), 376–379, 10.1038/nature12274.
9. [9] Cummins, N.W., Badley, A.D., Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis., 1, 2010, e99, 10.1038/cddis.2010.77.
10. [10] Burdo, T.H., Lentz, M.R., Autissier, P., Krishnan, A., Halpern, E., Letendre, S., et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. Infect. Dis. 204 (2011), 154–163, 10.1093/infdis/jir214.
11. [11] Vinikoor, M.J., Cope, A., Gay, C.L., Ferrari, G., McGee, K.S., Kuruc, J.D., et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J. Acquir. Immune Defic. Syndr. 62 (2013), 505–508, 10.1097/QAI.0b013e318285cd33.
12. [12] Dagenais-Lussier, X., Mouna, A., Routy, J.-P., Tremblay, C., Sekaly, R.-P., El-Far, M., et al. Current topics in HIV-1 pathogenesis: the emergence of deregulated immuno-metabolism in HIV-infected subjects. Cytokine Growth Factor Rev., 2015, 10.1016/j.cytogfr.2015.09.001.
13. [13] Le, T., Wright, E.J., Smith, D.M., He, W., Catano, G., Okulicz, J.F., et al. Enhanced CD4 + T-cell recovery with earlier HIV-1 antiretroviral therapy. N. Engl. J. Med. 368 (2013), 218–230, 10.1056/NEJMoa1110187.
14. [14] Kloosterboer, N., Groeneveld, P.H.P., Jansen, C.A., van der Vorst, T.J.K., Koning, F., Winkel, C.N., et al. Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus. Virology 339 (2005), 70–80, 10.1016/j.virol.2005.06.001.
15. [15] Lambotte, O., Delfraissy, J.-F., HIV controllers: a homogeneous group of HIV-1 infected patients with a spontaneous control of viral replication. Pathol. Biol. (Paris) 54 (2006), 566–571, 10.1016/j.patbio.2006.07.035.
16. [16] Mendoza, D., Johnson, S.A., Peterson, B.A., Natarajan, V., Salgado, M., Dewar, R.L., et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 119 (2012), 4645–4655, 10.1182/blood-2011-10-381996.
17. [17] Crowell, T. a, Gebo, K. a, Blankson, J.N., Korthuis, P.T., Yehia, B.R., Rutstein, R.M., et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J. Infect. Dis., 2014, 1–11, 10.1093/infdis/jiu809.
18. [18] Pereyra, F., Lo, J., Triant, V.A., Wei, J., Buzon, M.J., Fitch, K.V., et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 26 (2012), 2409–2412, 10.1097/QAD.0b013e32835a9950.
19. [19] Coffin, J.M., Hughes, S.H., Varmus, H.E., Retroviruses. 1997.
20. [20] Lindemann, D., Steffen, I., Pöhlmann, S., Cellular entry of retroviruses. Adv. Exp. Med. Biol. 790 (2013), 128–149, 10.1007/978-1-4614-7651-1_7.
21. [21] Bossart, K.N., Fusco, D.L., Broder, C.C., Viral Entry into Host Cells. 2013, 10.1007/978-1-4614-7651-1.
22. [22] Keele, B.F., Estes, J.D., Barriers to mucosal transmission of immunodeficiency viruses. Blood 118 (2011), 839–846, 10.1182/blood-2010-12-325860.
23. [23] Shaw, G.M., Hunter, E., HIV transmission. Cold Spring Harb. Perspect. Med., 2, 2012, 10.1101/cshperspect.a006965.
24. [24] Miller, C.J., Li, Q., Abel, K., Kim, E.-Y., Ma, Z.-M., Wietgrefe, S., et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79 (2005), 9217–9227, 10.1128/JVI.79.14.9217-9227.2005.
25. [25] Matreyek, K.A., Engelman, A., Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes. Viruses 5 (2013), 2483–2511, 10.3390/v5102483.
26. [26] Coiras, M., López-Huertas, M.R., Pérez-Olmeda, M., Alcamí, J., Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 7 (2009), 798–812, 10.1038/nrmicro2223.
27. [27] Wang, W.K., Chen, M.Y., Chuang, C.Y., Jeang, K.T., Huang, L.M., Molecular biology of human immunodeficiency virus type 1. J. Microbiol. Immunol. Infect. 33 (2000), 131–140 (http://www.ncbi.nlm.nih.gov/pubmed/11045374, accessed March 6, 2016).
28. [28] Nolan, D., Mallal, S., Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir. Ther. 9 (2004), 849–863 (http://www.ncbi.nlm.nih.gov/pubmed/15651744, accessed March 6, 2016).
29. [29] del M. Gutierrez, M., Mateo, M.G., Vidal, F., Domingo, P., The toxicogenetics of antiretroviral therapy: the evil inside. Curr. Med. Chem. 18 (2011), 209–219 (http://www.ncbi.nlm.nih.gov/pubmed/21110805, accessed March 6, 2016).
30. [30] Nolan, D., Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63 (2003), 2555–2574 (http://www.ncbi.nlm.nih.gov/pubmed/14636077, accessed March 6, 2016).
31. [31] Messiaen, P., Wensing, A.M.J., Fun, A., Nijhuis, M., Brusselaers, N., Vandekerckhove, L., Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS ONE, 8, 2013, e52562, 10.1371/journal.pone.0052562.
32. [32] DHHS, Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. 2015.
33. [33] UNAIDS, 90–90–90 An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf, 2014 (accessed January 10, 2016).
34. [34] Baral, S., Logie, C.H., Grosso, A., Wirtz, A.L., Beyrer, C., Modified social ecological model: a tool to guide the assessment of the risks and risk contexts of HIV epidemics. BMC Public Health, 13, 2013, 482, 10.1186/1471-2458-13-482.
35. [35] Walensky, R.P., Combination HIV prevention: the value and interpretation of mathematical models. Curr. HIV/AIDS Rep. 10 (2013), 195–198, 10.1007/s11904-013-0167-7.
36. [36] Galárraga, O., Colchero, M.A., Wamai, R.G., Bertozzi, S.M., HIV prevention cost-effectiveness: a systematic review. BMC Public Health, 9(Suppl. 1), 2009, S5, 10.1186/1471–2458-9-S1-S5.
37. [37] Johnson, B.T., Scott-Sheldon, L.A.J., Carey, M.P., Meta-synthesis of health behavior change meta-analyses. Am. J. Public Health 100 (2010), 2193–2198, 10.2105/AJPH.2008.155200.
38. [38] Noar, S.M., Behavioral interventions to reduce HIV-related sexual risk behavior: review and synthesis of meta-analytic evidence. AIDS Behav. 12 (2008), 335–353, 10.1007/s10461-007-9313-9.
39. [39] Berg, R.C., Ross, M.W., Tikkanen, R., The effectiveness of MI4MSM: how useful is motivational interviewing as an HIV risk prevention program for men who have sex with men? A systematic review. AIDS Educ. Prev. 23 (2011), 533–549, 10.1521/aeap.2011.23.6.533.
40. [40] Scott-Sheldon, L. a J., Johnson, B.T., Eroticizing creates safer sex: a research synthesis. J. Prim. Prev. 27 (2006), 619–640, 10.1007/s10935–006–0059-3.
41. [41] Kaufman, Z.a., Spencer, T.S., Ross, D.a., Effectiveness of sport-based HIV prevention interventions: a systematic review of the evidence. AIDS Behav. 17 (2013), 987–1001, 10.1007/s10461–012–0348-1.
42. [42] Eaton, L.A., Huedo-Medina, T.B., Kalichman, S.C., Pellowski, J.A., Sagherian, M.J., Warren, M., et al. Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages. Am. J. Public Health 102 (2012), e34–e44, 10.2105/AJPH.2012.300968.
43. [43] Fonner, V.A., Denison, J., Kennedy, C.E., O'Reilly, K., Sweat, M., Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane Database Syst. Rev., 9, 2012, CD001224, 10.1002/14651858.CD001224.pub4.
44. [44] Hall, H.I., Holtgrave, D.R., Maulsby, C., HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS 26 (2012), 893–896, 10.1097/QAD.0b013e328351f73f.
45. [45] Granich, R.M., Gilks, C.F., Dye, C., De Cock, K.M., Williams, B.G., Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373 (2009), 48–57, 10.1016/S0140-6736(08)61697-9.
46. [46] World Health Organization, Consolidated Guidelines on HIV Testing Services 2015. 2015.
47. [47] Cherutich, P., Bunnell, R., Mermin, J., HIV testing: Current practice and future directions. Curr. HIV/AIDS Rep. 10 (2013), 134–141, 10.1007/s11904-013-0158-8.
48. [48] Weller, S.C., A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc. Sci. Med. 36 (1993), 1635–1644, 10.1016/0277-9536(93)90352-5.
49. [49] Charania, M.R., Crepaz, N., Guenther-Gray, C., Henny, K., Liau, A., Willis, L.A., et al. Efficacy of structural-level condom distribution interventions: a meta-analysis of U.S. and International Studies, 1998–2007. AIDS Behav. 15 (2010), 1283–1297, 10.1007/s10461-010-9812-y.
50. [50] Noar, S.M., Carlyle, K., Cole, C., Why communication is crucial: meta-analysis of the relationship between safer sexual communication and condom use. J. Health Commun. 11 (2006), 365–390, 10.1080/10810730600671862.
51. [51] Widman, L., Noar, S.M., Choukas-Bradley, S., Francis, D.B., Adolescent sexual health communication and condom use: a meta-analysis. Health Psychol. 33 (2014), 1113–1124, 10.1037/hea0000112.
52. [52] Rojanapithayakorn, W., Hanenberg, R., The 100% condom program in Thailand. AIDS 10 (1996), 1–7, 10.1097/00002030-199601000-00001.
53. [53] Kerrigan, D., Moreno, L., Rosario, S., Sweat, M., Adapting the Thai 100% condom programme: Developing a culturally appropriate model for the Dominican Republic. Cult. Health Sex. 3 (2001), 221–240, 10.1080/136910501750153049.
54. [54] Huang, Z., Wang, M., Fu, L., Fang, Y., Hao, J., Tao, F., et al. Intervention to increase condom use and HIV testing among men who have sex with men in China: a meta-analysis. AIDS Res. Hum. Retrovir. 29 (2013), 441–448, 10.1089/AID.2012.0151.
55. [55] Swanton, R., Allom, V., Mullan, B., A meta-analysis of the effect of new-media interventions on sexual-health behaviours. Sex. Transm. Infect. 91 (2015), 14–20, 10.1136/sextrans-2014-051743.
56. [56] Bailey, R.C., Moses, S., Parker, C.B., Agot, K., Maclean, I., Krieger, J.N., et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369 (2007), 643–656, 10.1016/S0140-6736(07)60312-2 (S0140-6736(07)60312-2 [pii).
57. [57] Gray, R.H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369 (2007), 657–666, 10.1016/S0140-6736(07)60313-4.
58. [58] Hayashi, Y., Kohri, K., Circumcision related to urinary tract infections, sexually transmitted infections, human immunodeficiency virus infections, and penile and cervical cancer. Int. J. Urol. 20 (2013), 769–775, 10.1111/iju.12154.
59. [59] Klavs, I., Hamers, F.F., Male circumcision in Slovenia: results from a national probability sample survey. Sex. Transm. Infect. 84 (2008), 49–50, 10.1136/sti.2007.027524.
60. [60] Chemtob, D., Op de Coul, E., van Sighem, A., Mor, Z., Cazein, F., Semaille, C., Impact of male circumcision among heterosexual HIV cases: comparisons between three low HIV prevalence countries. Isr. J. Health Policy Res., 4, 2015, 36, 10.1186/s13584-015-0033-8.
61. [61] World Health Organizsation, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2013.
62. [62] Cardo, D.M., Culver, D.H., Ciesielski, C.A., Srivastava, P.U., Marcus, R., Abiteboul, D., et al. A case–control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N. Engl. J. Med. 337 (1997), 1485–1490, 10.1056/NEJM199711203372101.
63. [63] Borba Brum, M.C., Dantas Filho, F.F., Yates, Z.B., Verçoza Viana, M.C., Martin Chaves, E.B., Trindade, D.M., HIV seroconversion in a health care worker who underwent postexposure prophylaxis following needlestick injury. Am. J. Infect. Control 41 (2013), 471–472, 10.1016/j.ajic.2012.05.016.
64. [64] Pierce, A.B., Yohannes, K., Guy, R., Watson, K.M., Armishaw, J., Price, B., et al. HIV seroconversions among male non-occupational post-exposure prophylaxis service users: a data linkage study. Sex. Health, 8, 2011, 179, 10.1071/SH10063.
65. [65] Foster, R., McAllister, J., Read, T.R., Pierce, A.B., Richardson, R., McNulty, A., et al. Single-tablet emtricitabine-rilpivirine-tenofovir as HIV postexposure prophylaxis in men who have sex with men. Clin. Infect. Dis. 61 (2015), 1336–1341, 10.1093/cid/civ511.
66. [66] Fitzpatrick, L.J., Egan, D.J., Cowan, E., Savitsky, L.M., Kushner, J.D., Calderon, Y., et al. Nonoccupational post-exposure prophylaxis for HIV in New York State Emergency Departments. J. Int. Assoc. Provid. AIDS Care 13 (2014), 539–546, 10.1177/2325957414553847.
67. [67] Burns, D.N., Grossman, C., Turpin, J., Elharrar, V., Veronese, F., Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies. Curr. HIV/AIDS Rep. 11 (2014), 393–403, 10.1007/s11904-014-0234-8.
68. [68] Jiang, J., Yang, X., Ye, L., Zhou, B., Ning, C., Huang, J., et al. Pre-exposure prophylaxis for the prevention of hiv infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS ONE, 9, 2014, e87674, 10.1371/journal.pone.0087674.
69. [69] Grant, R.M., Lama, J.R., Anderson, P.L., McMahan, V., Liu, A.Y., Vargas, L., et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363 (2010), 2587–2599, 10.1056/NEJMoa1011205.
70. [70] Baeten, J.M., Donnell, D., Mugo, N.R., Ndase, P., Thomas, K.K., Campbell, J.D., et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect. Dis. 14 (2014), 1055–1064, 10.1016/S1473-3099(14)70937-5.
71. [71] Thigpen, M.C., Kebaabetswe, P.M., Paxton, L.A., Smith, D.K., Rose, C.E., Segolodi, T.M., et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367 (2012), 423–434, 10.1056/NEJMoa1110711.
72. [72] Molina, J.-M., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373 (2015), 2237–2246, 10.1056/NEJMoa1506273.
73. [73] Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P.a., Leethochawalit, M., et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381 (2013), 2083–2090, 10.1016/S0140–6736(13)61127–7.
74. [74] Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367 (2012), 411–422, 10.1056/NEJMoa1202614.
75. [75] Marrazzo, J.M., Ramjee, G., Richardson, B.A., Gomez, K., Mgodi, N., Nair, G., et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372 (2015), 509–518, 10.1056/NEJMoa1402269.
76. [76] Cottrell, M.L., Kashuba, A.D.M., Topical microbicides and HIV prevention in the female genital tract. J. Clin. Pharmacol. 54 (2014), 603–615, 10.1002/jcph.292.
77. [77] Hurt, C.B., Eron, J.J., Cohen, M.S., Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?. Clin. Infect. Dis. 53 (2011), 1265–1270, 10.1093/cid/cir684.
78. [78] Lehman, D.A., Baeten, J.M., McCoy, C.O., Weis, J.F., Peterson, D., Mbara, G., et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J. Infect. Dis. 211 (2015), 1211–1218, 10.1093/infdis/jiu677.
79. [79] Gomez, G.B., Borquez, A., Case, K.K., Wheelock, A., Vassall, A., Hankins, C., The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med., 10, 2013, e1001401, 10.1371/journal.pmed.1001401.
80. [80] World Health Organization, Policy Brief: Pre-Exposure Prophylaxis. Policy, 2015, 1–2 (http://apps.who.int/iris/bitstream/10665/197906/1/WHO_HIV_2015.48_eng.pdf?ua=1, accessed March 7, 2016).
81. [81] World Health Organization, Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. http://www.ncbi.nlm.nih.gov/pubmed/26598776, 2015 (accessed January 8, 2016).
82. [82] Domanska, C.A., Teitelman, A.M., Factors that affect acceptance of HIV microbicides among women. Collegian 19 (2012), 23–32 (http://www.ncbi.nlm.nih.gov/pubmed/22482279, accessed March 7, 2016).
83. [83] Abdool Karim, Q., Abdool Karim, S.S., Frohlich, J.A., Grobler, A.C., Baxter, C., Mansoor, L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329 (2010), 1168–1174, 10.1126/science.1193748.
84. [84] Baeten, J.M., Palanee-Phillips, T., Brown, E.R., Schwartz, K., Soto-Torres, L.E., Govender, V., et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med., 2016, 10.1056/NEJMoa1506110.
85. [85] Olsen, J.S., Easterhoff, D., Dewhurst, S., Advances in HIV microbicide development. Future Med. Chem. 3 (2011), 2101–2116, 10.4155/fmc.11.153.
86. [86] Nunes, R., Sarmento, B., Neves, J. das, Formulation and delivery of anti-HIV rectal microbicides: advances and challenges. J. Control. Release 194 (2014), 278–294, 10.1016/j.jconrel.2014.09.013.
87. [87] Gulick, R.M., Mellors, J.W., Havlir, D., Eron, J.J., Gonzalez, C., McMahon, D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337 (1997), 734–739, 10.1056/NEJM199709113371102.
88. [88] Montaner, J.S., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. J. Am. Med. Assoc. 279 (1998), 930–937 (http://www.ncbi.nlm.nih.gov/pubmed/9544767, accessed January 10, 2016).
89. [89] Ho, D.D., Time to hit HIV, early and hard. N. Engl. J. Med. 333 (1995), 450–451, 10.1056/NEJM199508173330710.
90. [90] El-Sadr, W.M., Lundgren, J.D., Neaton, J.D., Gordin, F., Abrams, D., Arduino, R.C., et al. CD4 + Count–Guided Interruption of Antiretroviral Treatment. N. Engl. J. Med. 355 (2006), 2283–2296, 10.1056/NEJMoa062360.
91. [91] EACS, European HIV Guideline. eighth ed., 2015.
92. [92] Cahn, P., Andrade-Villanueva, J., Arribas, J.R., Gatell, J.M., Lama, J.R., Norton, M., et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomise. Lancet Infect. Dis. 14 (2014), 572–580, 10.1016/S1473-3099(14)70736-4.
93. [93] Figueroa, M.I., Sued, O., Patterson, P., Gun, A., Rolon, M.J., Cahn, P., Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. 15th Eur. AIDS Conf., Barcelona, 2015 (p. Abstract LBPS4/).
94. [94] Arribas, J.R., Girard, P.-M., Landman, R., Pich, J., Mallolas, J., Martínez-Rebollar, M., et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a random. Lancet Infect. Dis. 15 (2015), 785–792, 10.1016/S1473-3099(15)00096-1.
95. [95] Mondi, A., Fabbiani, M., Ciccarelli, N., Colafigli, M., D'Avino, A., Borghetti, A., et al. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. J. Antimicrob. Chemother. 70 (2015), 1843–1849, 10.1093/jac/dkv037.
96. [96] Perez-Molina, J.A., Rubio, R., Rivero, A., Pasquau, J., Suárez-Lozano, I., Riera, M., et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect. Dis. 15 (2015), 775–784, 10.1016/S1473-3099(15)00097-3.
97. [97] Taiwo, B., Zheng, L., Gallien, S., Matining, R.M., Kuritzkes, D.R., Wilson, C.C., et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25 (2011), 2113–2122, 10.1097/QAD.0b013e32834bbaa9.
98. [98] Raffi, F., Babiker, A.G., Richert, L., Molina, J.-M., George, E.C., Antinori, A., et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet (Lond. Engl.) 384 (2014), 1942–1951, 10.1016/S0140–6736(14)61170–3.
99. [99] Sperling, R.S., Shapiro, D.E., Coombs, R.W., Todd, J.A., Herman, S.A., McSherry, G.D., et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N. Engl. J. Med. 335 (1996), 1621–1629.
100. [100] Cohen, M.S., Chen, Y.Q., McCauley, M., Gamble, T., Hosseinipour, M.C., Kumarasamy, N., et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365 (2011), 493–505, 10.1056/NEJMoa1105243.
101. [101] Del Romero, J., Río, I., Castilla, J., Baza, B., Paredes, V., Vera, M., et al. Absence of transmission from HIV-infected individuals with HAART to their heterosexual serodiscordant partners. Enferm. Infecc. Microbiol. Clin., 2014, 10.1016/j.eimc.2014.10.020.
102. [102] Rodger, A., Bruun, T., Cambiano, V., Vernazza, P., Estrada, V., Van Lunzen, J., et al. HIV transmission risk through condomless sex if the HIV positive partner is on suppressive ART: PARTNER study. CROI, 2014, 153LB.
103. [103] Montaner, J.S.G., Lima, V.D., Harrigan, P.R., Lourenço, L., Yip, B., Nosyk, B., et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS ONE, 9, 2014, e87872, 10.1371/journal.pone.0087872.
104. [104] Smith, M.K., Westreich, D., Liu, H., Zhu, L., Wang, L., He, W., et al. Treatment to prevent HIV transmission in serodiscordant couples in Henan, China, 2006 to 2012. Clin. Infect. Dis. 61 (2015), 111–119, 10.1093/cid/civ200.
105. [105] Vandormael, A., Newell, M.-L., Bärnighausen, T., Tanser, F., Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004–12: a prospective cohort study. Lancet. Glob. Health 2 (2014), e209–e215, 10.1016/S2214-109X(14)70018-X.
106. [106] Kretzschmar, M.E., Schim van der Loeff, M.F., Birrell, P.J., De Angelis, D., Coutinho, R.A., Prospects of elimination of HIV with test-and-treat strategy. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 15538–15543, 10.1073/pnas.1301801110.
107. [107] Powers, K.A., Ghani, A.C., Miller, W.C., Hoffman, I.F., Pettifor, A.E., Kamanga, G., et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (Lond. Engl.) 378 (2011), 256–268, 10.1016/S0140–6736(11)60842–8.
108. [108] Hoffmann, C.J., Gallant, J.E., Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels. Infect. Dis. Clin. N. Am. 28 (2014), 549–561, 10.1016/j.idc.2014.08.003.
109. [109] Eaton, E.F., Saag, M.S., Mugavero, M., Engagement in human immunodeficiency virus care: linkage, retention, and antiretroviral therapy adherence. Infect. Dis. Clin. N. Am. 28 (2014), 355–369, 10.1016/j.idc.2014.06.004.
110. [110] Gulick, R.M., Choosing initial antiretroviral therapy: current recommendations for initial therapy and newer or investigational agents. Top. Antivir. Med. 23 (2015), 128–131 (accessed January 9, 2016) http://www.ncbi.nlm.nih.gov/pubmed/26713502.
111. [111] Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müssig, A., Allers, K., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360 (2009), 692–698, 10.1056/NEJMoa0802905.
112. [112] Chéret, A., Bacchus-Souffan, C., Avettand-Fenoël, V., Mélard, A., Nembot, G., Blanc, C., et al. Combined ART started during acute HIV infection protects central memory CD4 + T cells and can induce remission. J. Antimicrob. Chemother. 70 (2015), 2108–2120, 10.1093/jac/dkv084.
113. [113] Mylvaganam, G.H., Silvestri, G., Amara, R.R., HIV therapeutic vaccines: moving towards a functional cure. Curr. Opin. Immunol. 35 (2015), 1–8, 10.1016/j.coi.2015.05.001.
114. [114] Cummins, N.W., Badley, A.D., Making sense of how HIV kills infected CD4 T cells: implications for HIV cure. Mol. Cell. Ther., 2, 2014, 20, 10.1186/2052-8426-2-20.
115. [115] Dahabieh, M.S., Battivelli, E., Verdin, E., Understanding HIV latency: the road to an HIV cure. Annu. Rev. Med. 66 (2015), 407–421, 10.1146/annurev-med-092112-152941.
116. [116] Archin, N.M., Margolis, D.M., Emerging strategies to deplete the HIV reservoir. Curr. Opin. Infect. Dis. 27 (2014), 29–35, 10.1097/QCO.0000000000000026.
117. [117] Maenza, J., Tapia, K., Holte, S., Stekler, J.D., Stevens, C.E., Mullins, J.I., et al. How often does treatment of primary HIV lead to post-treatment control?. Antivir. Ther., 2015, 10.3851/IMP2963.
118. [118] Fidler, S., Olson, A., Fox, J., Phillips, A., Morrison, C., Thornhill, J., et al. The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. J. Int. AIDS Soc., 17, 2014, 19820 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4225245&tool=pmcentrez&rendertype=abstract, accessed October 16, 2015).
119. [119] Goujard, C., Girault, I., Rouzioux, C., Lécuroux, C., Deveau, C., Chaix, M.-L., et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir. Ther. 17 (2012), 1001–1009, 10.3851/IMP2273.
120. [120] Sáez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog., 9, 2013, e1003211, 10.1371/journal.ppat.1003211.
121. [121] Ananworanich, J., Schuetz, A., Vandergeeten, C., Sereti, I., de Souza, M., Rerknimitr, R., et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE, 7, 2012, e33948, 10.1371/journal.pone.0033948.
122. [122] Passaes, C.P., Sáez-Cirión, A., HIV cure research: advances and prospects. Virology 454-455 (2014), 340–352, 10.1016/j.virol.2014.02.021.
123. [123] Prins, J.M., Jurriaans, S., van Praag, R.M., Blaak, H., van Rij, R., Schellekens, P.T., et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13 (1999), 2405–2410, 10.1097/00002030-199912030-00012.
124. [124] Kulkosky, J., Nunnari, G., Otero, M., Calarota, S., Dornadula, G., Zhang, H., et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186 (2002), 1403–1411, 10.1086/344357.
125. [125] Deeks, S.G., HIV: shock and kill. Nature 487 (2012), 439–440, 10.1038/487439a.
126. [126] Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366 (2005), 549–555, 10.1016/S0140-6736(05)67098-5.
127. [127] Archin, N.M., Cheema, M., Parker, D., Wiegand, A., Bosch, R.J., Coffin, J.M., et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4 + cell infection. PLoS ONE, 5, 2010, e9390, 10.1371/journal.pone.0009390.
128. [128] Routy, J.P., Tremblay, C.L., Angel, J.B., Trottier, B., Rouleau, D., Baril, J.G., et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 13 (2012), 291–296, 10.1111/j.1468-1293.2011.00975.x.
129. [129] Archin, N.M., Bateson, R., Tripathy, M.K., Crooks, A.M., Yang, K.-H., Dahl, N.P., et al. HIV-1 expression within resting CD4 + T cells after multiple doses of vorinostat. J. Infect. Dis. 210 (2014), 728–735, 10.1093/infdis/jiu155.
130. [130] Søgaard, O.S., Graversen, M.E., Leth, S., Olesen, R., Brinkmann, C.R., Nissen, S.K., et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog., 11, 2015, e1005142, 10.1371/journal.ppat.1005142.
131. [131] Rasmussen, T. a, Tolstrup, M., Brinkmann, C.R., Olesen, R., Erikstrup, C., Solomon, A., et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1 (2014), e13–e21, 10.1016/S2352–3018(14)70014–1.
132. [132] Shang, H., Ding, J., Yu, S., Wu, T., Zhang, Q., Liang, F., Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacol. Sin. 36 (2015), 908–916, 10.1038/aps.2015.22.
133. [133] Spivak, A.M., Planelles, V., HIV-1 eradication: early trials (and tribulations). Trends Mol. Med. 22 (2015), 10–27, 10.1016/j.molmed.2015.11.004.
134. [134] Shan, L., Deng, K., Shroff, N.S., Durand, C.M., Rabi, S.A., Yang, H.-C., et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36 (2012), 491–501, 10.1016/j.immuni.2012.01.014.
135. [135] Jones, R.B., Walker, B.D., HIV-specific CD8 + T cells and HIV eradication. J. Clin. Invest., 2016, 1–9, 10.1172/JCI80566.
136. [136] Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228, 10.1038/nature12744.
137. [137] Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O.K., Plishka, R., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280, 10.1038/nature12746.
138. [138] Croce, M., Orengo, A.M., Azzarone, B., Ferrini, S., Immunotherapeutic applications of IL-15. Immunotherapy 4 (2012), 957–969, 10.2217/imt.12.92.
139. [139] Levy, Y., Lacabaratz, C., Weiss, L., Viard, J.-P., Goujard, C., Lelièvre, J.-D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119 (2009), 997–1007, 10.1172/JCI38052.
140. [140] Kaufmann, D.E., Walker, B.D., PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 182 (2009), 5891–5897, 10.4049/jimmunol.0803771.
141. [141] Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., Lee, G., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370 (2014), 901–910, 10.1056/NEJMoa1300662.
142. [142] Davidson, B.L., McCray, P.B., Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12 (2011), 329–340, 10.1038/nrg2968.
143. [143] Boutwell, C.L., Rolland, M.M., Herbeck, J.T., Mullins, J.I., Allen, T.M., Viral evolution and escape during acute HIV-1 infection. J. Infect. Dis. 202 (2010), S309–S314, 10.1086/655653 (Suppl.).
144. [144] Burton, D.R., Desrosiers, R.C., Doms, R.W., Koff, W.C., Kwong, P.D., Moore, J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004), 233–236, 10.1038/ni0304-233.
145. [145] González, N., Alvarez, A., Alcamí, J., Broadly neutralizing antibodies and their significance for HIV-1 vaccines. Curr. HIV Res. 8 (2010), 602–612 (http://www.ncbi.nlm.nih.gov/pubmed/21054253, accessed October 16, 2015).
146. [146] Lewis, G.K., DeVico, A.L., Gallo, R.C., Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 15614–15621, 10.1073/pnas.1413550111.
147. [147] Alter, G., Moody, M.A., The humoral response to HIV-1: new insights, renewed focus. J. Infect. Dis. 202 (2010), S315–S322, 10.1086/655654 (Suppl.).
148. [148] McCoy, L.E., Weiss, R.A., Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 210 (2013), 209–223, 10.1084/jem.20121827.
149. [149] Shingai, M., Donau, O.K., Plishka, R.J., Buckler-White, A., Mascola, J.R., Nabel, G.J., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211 (2014), 2061–2074, 10.1084/jem.20132494.
150. [150] Caskey, M., Klein, F., Lorenzi, J.C.C., Seaman, M.S., West, A.P., Buckley, N., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491, 10.1038/nature14411.
151. [151] Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361 (2009), 2209–2220, 10.1056/NEJMoa0908492.
152. [152] Rao, M., Peachman, K.K., Kim, J., Gao, G., Alving, C.R., Michael, N.L., et al. HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr. HIV Res. 11 (2013), 427–438 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4086350&tool=pmcentrez&rendertype=abstract, accessed December 19, 2015).
153. [153] Climent, N., Guerra, S., García, F., Rovira, C., Miralles, L., Gómez, C.E., et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS ONE, 6, 2011, e19644, 10.1371/journal.pone.0019644.
154. [154] Martinez-Navio, J.M., Climent, N., Gallart, T., Lluis, C., Franco, R., An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV. Immunol. Cell Biol. 90 (2012), 594–600, 10.1038/icb.2011.81.
155. [155] Climent, N., Munier, S., Piqué, N., García, F., Pavot, V., Primard, C., et al. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. Vaccine 32 (2014), 6266–6276, 10.1016/j.vaccine.2014.09.010.
156. [156] García, F., Plana, M., Climent, N., León, A., Gatell, J.M., Gallart, T., Dendritic cell based vaccines for HIV infection: the way ahead. Hum. Vaccin. Immunother. 9 (2013), 2445–2452 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3981855&tool=pmcentrez&rendertype=abstract, accessed January 11, 2016).
157. [157] Peña, J., Frías, M., Castro-Orgaz, L., González, R., García, F., Gallart, T., et al. Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection. Viral Immunol. 25 (2012), 37–44, 10.1089/vim.2011.0044.
158. [158] García, F., Climent, N., Guardo, A.C., Gil, C., León, A., Autran, B., et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med., 5, 2013, 166ra2, 10.1126/scitranslmed.3004682.
159. [159] Andrés, C., Plana, M., Guardo, A.C., Alvarez-Fernández, C., Climent, N., Gallart, T., et al. HIV-1 reservoir dynamics after vaccination and antiretroviral therapy interruption are associated with dendritic cell vaccine-induced T cell responses. J. Virol. 89 (2015), 9189–9199, 10.1128/JVI.01062-15.
160. [160] Cope, A.B., Powers, K.A., Kuruc, J.D., Leone, P.A., Anderson, J.A., Ping, L.-H., et al. Ongoing HIV transmission and the HIV care continuum in North Carolina. PLoS ONE, 10, 2015, e0127950, 10.1371/journal.pone.0127950.
161. [161] Brenner, B.G., Roger, M., Routy, J.-P., Moisi, D., Ntemgwa, M., Matte, C., et al. High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195 (2007), 951–959, 10.1086/512088.
162. [162] Shafiee, H., Wang, S., Inci, F., Toy, M., Henrich, T.J., Kuritzkes, D.R., et al. Emerging technologies for point-of-care management of HIV infection. Annu. Rev. Med. 66 (2015), 387–405, 10.1146/annurev-med-092112-143017.
163. [163] Shafiee, H., Jahangir, M., Inci, F., Wang, S., Willenbrecht, R.B.M., Giguel, F.F., et al. Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small 9 (2013), 2553–2563, 10.1002/smll.201202195 (2478).
164. [164] Inci, F., Tokel, O., Wang, S., Gurkan, U.A., Tasoglu, S., Kuritzkes, D.R., et al. Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano 7 (2013), 4733–4745, 10.1021/nn3036232.
165. [165] Ming, K., Kim, J., Biondi, M.J., Syed, A., Chen, K., Lam, A., et al. Integrated quantum dot barcode smartphone optical device for wireless multiplexed diagnosis of infected patients. ACS Nano 9 (2015), 3060–3074, 10.1021/nn5072792.
166. [166] Date, A.A., Shibata, A., McMullen, E., La Bruzzo, K., Bruck, P., Belshan, M., et al. Thermosensitive gel containing cellulose acetate phthalate-efavirenz combination nanoparticles for prevention of HIV-1 infection. J. Biomed. Nanotechnol. 11 (2015), 416–427 (http://www.ncbi.nlm.nih.gov/pubmed/26307825, accessed January 19, 2016).
167. [167] Chaowanachan, T., Krogstad, E., Ball, C., Woodrow, K. a, Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One, 8, 2013, e61416, 10.1371/journal.pone.0061416.
168. [168] Gu, J., Yang, S., Ho, E.A., Biodegradable film for the targeted delivery of siRNA-loaded nanoparticles to vaginal immune cells. Mol. Pharm. 12 (2015), 2889–2903, 10.1021/acs.molpharmaceut.5b00073.
169. [169] Moscicki, A.-B., Kaul, R., Ma, Y., Scott, M.E., Daud, I.I., Bukusi, E.A., et al. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J. Acquir. Immune Defic. Syndr. 59 (2012), 134–140, 10.1097/QAI.0b013e31823f2aeb.
170. [170] Sánchez-Rodríguez, J., Vacas-Córdoba, E., Gómez, R., De La Mata, F.J., Muñoz-Fernández, M.Á., Nanotech-derived topical microbicides for HIV prevention: the road to clinical development. Antivir. Res. 113 (2015), 33–48, 10.1016/j.antiviral.2014.10.014.
171. [171] Clayden, P., Collins, S., Frick, M., Harrington, M., Horn, T., Jeffreys, R., et al. HIV, hepatitis C virus (HCV) and tuberculosis (TB): drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development. HIV Treat. Bull. 16 (2015), 1–163 (http://i-base.info/htb/wp-content/uploads/2015/07/2015-pipeline-report-web.pdf, accessed March 6, 2016).
172. [172] Levendosky, K., Mizenina, O., Martinelli, E., Jean-Pierre, N., Kizima, L., Rodriguez, A., et al. Griffithsin and Carrageenan combination to target herpes simplex virus 2 and human papillomavirus. Antimicrob. Agents Chemother. 59 (2015), 7290–7298, 10.1128/AAC.01816-15.
173. [173] Brügger, B., Krautkrämer, E., Tibroni, N., Munte, C.E., Rauch, S., Leibrecht, I., et al. Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology, 4, 2007, 70, 10.1186/1742-4690-4-70.
174. [174] Doll, T.A.P.F., Neef, T., Duong, N., Lanar, D.E., Ringler, P., Müller, S.A., et al. Optimizing the design of protein nanoparticles as carriers for vaccine applications. Nanomedicine 11 (2015), 1705–1713, 10.1016/j.nano.2015.05.003.
175. [175] Wahome, N., Pfeiffer, T., Ambiel, I., Yang, Y., Keppler, O.T., Bosch, V., et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem. Biol. Drug Des. 80 (2012), 349–357, 10.1111/j.1747-0285.2012.01423.x.
176. [176] Caucheteux, S.M., Mitchell, J.P., Ivory, M.O., Hirosue, S., Hakobyan, S., Dolton, G., et al. Polypropylene sulfide nanoparticle p24 vaccine promotes dendritic cell-mediated specific immune responses against HIV-1. J. Invest. Dermatol., 2016, 10.1016/j.jid.2016.01.033.
177. [177] Bell, I.R., Ives, J.A., Jonas, W.B., Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions. Dose-Response 12 (2014), 202–232, 10.2203/dose-response.13-025.Bell.
178. [178] Chiappetta, D. a, Hocht, C., Taira, C., Sosnik, A., Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Nanomedicine (London) 5 (2010), 11–23, 10.2217/nnm.09.90.
179. [179] Destache, C.J., Belgum, T., Goede, M., Shibata, A., Belshan, M. a, Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J. Antimicrob. Chemother. 65 (2010), 2183–2187, 10.1093/jac/dkq318.
180. [180] Basu, S., Mukherjee, B., Chowdhury, S.R., Paul, P., Choudhury, R., Kumar, A., et al. Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study. Int. J. Nanomedicine 7 (2012), 6049–6061, 10.2147/IJN.S38013.
181. [181] Harilall, S.-L., Choonara, Y.E., Tomar, L.K., Tyagi, C., Kumar, P., du Toit, L.C., et al. Development and in vivo evaluation of an implantable nano-enabled multipolymeric scaffold for the management of AIDS dementia complex (ADC). Int. J. Pharm. 496 (2015), 863–877, 10.1016/j.ijpharm.2015.10.025.
182. [182] Gendelman, H.E., Gelbard, H.A., Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Curr. Opin. HIV AIDS 9 (2014), 585–590, 10.1097/COH.0000000000000111.
183. [183] Gerson, T., Makarov, E., Senanayake, T.H., Gorantla, S., Poluektova, L.Y., Vinogradov, S.V., Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain. Nanomedicine 10 (2014), 177–185, 10.1016/j.nano.2013.06.012.
184. [184] Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., Sarmento, B., Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 65 (2013), 1816–1827, 10.1016/j.addr.2013.07.020.
185. [185] Spreen, W., Williams, P., Margolis, D., Ford, S.L., Crauwels, H., Lou, Y., et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J. Acquir. Immune Defic. Syndr. 67 (2014), 487–492, 10.1097/QAI.0000000000000365.
186. [186] Margolis, D.A., Boffito, M., Long-acting antiviral agents for HIV treatment. Curr. Opin. HIV AIDS 10 (2015), 246–252, 10.1097/COH.0000000000000169.
187. [187] Landovitz, R.J., Kofron, R., McCauley, M., The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr. Opin. HIV AIDS 11 (2016), 122–128, 10.1097/COH.0000000000000219.
188. [188] Mahajan, S.D., Aalinkeel, R., Law, W.C., Reynolds, J.L., Nair, B.B., Sykes, D.E., et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int. J. Nanomedicine 7 (2012), 5301–5314, 10.2147/IJN.S25871.
189. [189] Lenjisa, J.L., Woldu, M.A., Satessa, G.D., New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy. J. Nanobiotechnol., 12, 2014, 9, 10.1186/1477-3155-12-9.
190. [190] Wan, L., Pooyan, S., Hu, P., Leibowitz, M.J., Stein, S., Sinko, P.J., Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm. Res. 24 (2007), 2110–2119, 10.1007/s11095-007-9402-5.
191. [191] Lundin, K.E., Simonson, O.E., Moreno, P.M.D., Zaghloul, E.M., Oprea, I.I., Svahn, M.G., et al. Nanotechnology approaches for gene transfer. Genetica 137 (2009), 47–56, 10.1007/s10709-009-9372-0.
192. [192] Whitehead, K. a, Langer, R., Anderson, D.G., Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8 (2009), 129–138, 10.1038/nrd3182.
193. [193] Hori, Y., Winans, A.M., Huang, C.C., Horrigan, E.M., Irvine, D.J., Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 29 (2008), 3671–3682, 10.1016/j.biomaterials.2008.05.033.
194. [194] Lori, F., Calarota, S. a, Lisziewicz, J., Nanochemistry-based immunotherapy for HIV-1. Curr. Med. Chem. 14 (2007), 1911–1919, 10.2174/092986707781368513.
195. [195] Yu, X., Xu, F., Ramirez, N.-G.P., Kijewski, S.D.G., Akiyama, H., Gummuluru, S., et al. Dressing up nanoparticles: a membrane wrap to induce formation of the virological synapse. ACS Nano 9 (2015), 4182–4192, 10.1021/acsnano.5b00415.
196. [196] Kuo, Y.-C., Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 290 (2005), 161–172, 10.1016/j.ijpharm.2004.11.025.
197. [197] Kuo, Y.-C., Su, F.-L., Transport of stavudine, delavirdine, and saquinavir across the blood–brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 340 (2007), 143–152, 10.1016/j.ijpharm.2007.03.012.
198. [198] Kuo, Y.-C., Chen, H.-H., Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood–brain barrier. Int. J. Pharm. 327 (2006), 160–169, 10.1016/j.ijpharm.2006.07.044.
199. [199] Kuo, Y.-C., Lee, C.-L., Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood–brain barrier. Colloids Surf. B Biointerfaces 90 (2012), 75–82, 10.1016/j.colsurfb.2011.09.048.
200. [200] Kuo, Y.-C., Kuo, C.-Y., Electromagnetic interference in the permeability of saquinavir across the blood–brain barrier using nanoparticulate carriers. Int. J. Pharm. 351 (2008), 271–281, 10.1016/j.ijpharm.2007.09.020.
201. [201] Mahajan, S.D., Law, W.-C., Aalinkeel, R., Reynolds, J., Nair, B.B., Yong, K.-T., et al. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain. Methods Enzymol. 509 (2012), 41–60, 10.1016/B978-0-12-391858-1.00003-4.
202. [202] Shah, L.K., Amiji, M.M., Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23 (2006), 2638–2645, 10.1007/s11095-006-9101-7.
203. [203] Ece Gamsiz, D., Shah, L.K., Devalapally, H., Amiji, M.M., Carrier, R.L., A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells. Biotechnol. Bioeng. 101 (2008), 1072–1082, 10.1002/bit.21958.
204. [204] Neves, J. das, Araújo, F., Andrade, F., Amiji, M., Bahia, M.F., Sarmento, B., Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. Pharm. Res. 31 (2014), 1834–1845, 10.1007/s11095–013-1287-x.
205. [205] Neves, J. das, Araújo, F., Andrade, F., Michiels, J., Ariën, K.K., Vanham, G., et al. In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine. Mol. Pharm. 10 (2013), 2793–2807, 10.1021/mp4002365.
206. [206] Neves, J. das, Michiels, J., Ariën, K.K., Vanham, G., Amiji, M., Bahia, M.F., et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm. Res. 29 (2012), 1468–1484, 10.1007/s11095–011–0622-3.
207. [207] Tshweu, L., Katata, L., Kalombo, L., Chiappetta, D.A., Hocht, C., Sosnik, A., et al. Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. Nanomedicine (London) 9 (2014), 1821–1833, 10.2217/nnm.13.167.
208. [208] Borgmann, K., Rao, K.S., Labhasetwar, V., Ghorpade, A., Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res. Hum. Retrovir. 27 (2011), 853–862, 10.1089/AID.2010.0295.
209. [209] Makwana, V., Jain, R., Patel, K., Nivsarkar, M., Joshi, A., Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int. J. Pharm. 495 (2015), 439–446, 10.1016/j.ijpharm.2015.09.014.
210. [210] Alex, A., Paul, W., Chacko, A.J., Sharma, C.P., Enhanced delivery of lopinavir to the CNS using compritol-based solid lipid nanoparticles. Ther. Deliv. 2 (2011), 25–35 (http://www.ncbi.nlm.nih.gov/pubmed/22833923, accessed January 25, 2016).
211. [211] Kuo, Y.-C., Chen, H.-H., Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365 (2009), 206–213, 10.1016/j.ijpharm.2008.08.050.
212. [212] Duan, J., Freeling, J.P., Koehn, J., Shu, C., Ho, R.J.Y., Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J. Pharm. Sci. 103 (2014), 2520–2529, 10.1002/jps.24046.
213. [213] Kuo, Y.-C., Yu, H.-W., Polyethyleneimine/poly-(γ-glutamic acid)/poly(lactide-co-glycolide) nanoparticles for loading and releasing antiretroviral drug. Colloids Surf. B Biointerfaces 88 (2011), 158–164, 10.1016/j.colsurfb.2011.06.026.
214. [214] Yang, L., Chen, L., Zeng, R., Li, C., Qiao, R., Hu, L., et al. Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan-O-isopropyl-5′-O-d4T monophosphate conjugate. Bioorg. Med. Chem. 18 (2010), 117–123, 10.1016/j.bmc.2009.11.013.
215. [215] Imperiale, J.C., Nejamkin, P., Del Sole, M.J., Lanusse, C.E., Sosnik, A., Novel protease inhibitor-loaded nanoparticle-in-microparticle delivery system leads to a dramatic improvement of the oral pharmacokinetics in dogs. Biomaterials 37 (2015), 383–394, 10.1016/j.biomaterials.2014.10.026.
216. [216] Jiang, Y., Cao, S., Bright, D.K., Bever, A.M., Blakney, A.K., Suydam, I.T., et al. Nanoparticle-based ARV drug combinations for synergistic inhibition of cell-free and cell–cell HIV transmission. Mol. Pharm. 12 (2015), 4363–4374, 10.1021/acs.molpharmaceut.5b00544.
217. [217] Chiappetta, D.A., Hocht, C., Opezzo, J.A.W., Sosnik, A., Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (London) 8 (2013), 223–237, 10.2217/nnm.12.104.
218. [218] Raju, A., Reddy, A.J., Satheesh, J., Jithan, A.V., Preparation and characterisation of nevirapine oral nanosuspensions. Indian J. Pharm. Sci. 76 (2014), 62–71 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4007257&tool=pmcentrez&rendertype=abstract, accessed January 25, 2016).
219. [219] Gautam, N., Puligujja, P., Balkundi, S., Thakare, R., Liu, X.-M., Fox, H.S., et al. Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations. Antimicrob. Agents Chemother. 58 (2014), 7510–7519, 10.1128/AAC.04108-14.
220. [220] Puligujja, P., Balkundi, S.S., Kendrick, L.M., Baldridge, H.M., Hilaire, J.R., Bade, A.N., et al. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials 41 (2015), 141–150, 10.1016/j.biomaterials.2014.11.012.
221. [221] Jindal, N., Mehta, S.K., Nevirapine loaded Poloxamer 407/Pluronic P123 mixed micelles: optimization of formulation and in vitro evaluation. Colloids Surf. B Biointerfaces 129 (2015), 100–106, 10.1016/j.colsurfb.2015.03.030.
222. [222] Dutta, T., Garg, M., Jain, N.K., Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci. 34 (2008), 181–189, 10.1016/j.ejps.2008.04.002.
223. [223] Garrido, C., Simpson, C.A., Dahl, N.P., Bresee, J., Whitehead, D.C., Lindsey, E.A., et al. Gold nanoparticles to improve HIV drug delivery. Future Med. Chem. 7 (2015), 1097–1107, 10.4155/fmc.15.57.